

Shaping the Future of Myeloma Treatment



Ivan Borrello, MD

Associate Professor of Oncology
Johns Hopkins University
Baltimore, Maryland

Ivan Borrello completed his medical degree at the Medical College of Virginia. His postdoctoral studies included an internship and residency at the University of Chicago and a fellowship in medical oncology at Johns Hopkins Oncology Center.

Dr. Borrello's group has pioneered the use of marrow-infiltrating lymphocyte (MIL) cell therapy and established an adoptive cell therapy infrastructure at Johns Hopkins. In addition to the translational clinical work, his laboratory has focused on understanding the biology of the bone marrow microenvironment as it pertains to the tumor-specific T-cell response to augment the clinical efficacy of MIL cell therapy and to identify novel immune-based therapeutic approaches (including cancer vaccines), with an overarching goal of improving clinical outcomes in myeloma through the integration of immunotherapy into the clinical setting.

Dr. Borrello has published widely in, and he serves as a reviewer for, a number of peer-reviewed journals. He holds membership in several professional societies, and he is a Diplomate of the National Board of Medical Examiners, the American Board of Internal Medicine, and the American Board of Medical Oncology.